메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한진단검사의학회 Annals of Laboratory Medicine Annals of Laboratory Medicine 제39권 제5호
발행연도
2019.1
수록면
496 - 498 (3page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Dear Editor, Plasma cell myeloma (PCM) is the second most common hematologic neoplasm, with a worldwide aged-standardized incidence rate of 1.5/100,000 [1]. The introduction of new therapeutic modalities, including alkylating agents and autologous stem cell transplants (ASCT), has dramatically improved the prognosis of patients with PCM; unfortunately, this has been accompanied by an increase in the incidence of secondary neoplasms [1, 2]. Therapy-related ALL (t-ALL) is uncommon and far less understood than therapy-related AML. t-ALL as a secondary neoplasm in PCM patients is extremely rare, and only two cases have been reported so far [3-5]. We report two additional cases of t-ALL in PCM patients: one who was treated with alkylating agents and topoisomerase II inhibitors simultaneously and the other one who was treated with only topoisomerase II inhibitors. These two cases are first to be reported in Korea. As this was a case report, the Institutional Review Board of Asan Medical Center, Seoul, Korea, waived the requirement for informed consent.

목차

등록된 정보가 없습니다.

참고문헌 (8)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0